Medici and Yangtze River Pharmaceutical's wholly-owned subsidiary, Hailu Bio, reach a strategic partnership

Source: Shanghai Securities News · China Securities Network

Shanghai Securities News · China Securities Network reports (Reporter Qi Doudou) Recently, MEDIT and Shanghai Hai Lu Biotechnology Co., Ltd., a wholly owned subsidiary of Jiangsu Yanzijiang Pharmaceutical Group (hereinafter referred to as “Hai Lu Bio”), held a strategic cooperation signing ceremony. The two sides will carry out deep coordination in areas including preclinical R&D of new drugs, overseas expansion of projects, and introduction of new assets, jointly building an efficient, open, and internationalized R&D new ecosystem—from source innovation to IND application—leading high-quality development of China’s biopharmaceutical industry and advancing it further toward globalization.

MEDIT is a leading domestic one-stop CRO offering preclinical biopharmaceutical R&D services. Its services cover the entire process of drug discovery, pharmaceutical research, and preclinical research, and it builds R&D service platforms for novel molecular drugs such as antibodies, ADCs, mRNA vaccines, small nucleic acids, PROTAC, CGT, and others. With mature technical platforms and successful case studies, it has already helped multiple innovative drugs realize overseas expansion. As a wholly owned subsidiary of Jiangsu Yanzijiang Pharmaceutical Group and a core biopharmaceutical R&D platform, Hai Lu Bio has built a complete large-molecule innovative drug R&D system, ranging from target discovery and molecular design to preclinical development.

It is understood that since the cooperation began in 2010, MEDIT and Jiangsu Yanzijiang Pharmaceutical Group have maintained close project collaboration across multiple stages of preclinical R&D for new drugs. Under this strategic cooperation, the two sides will conduct customized R&D collaboration using flexible models such as outsourced R&D and FTE/FFS, fully covering one-stop preclinical services for innovative drugs, including early discovery, pharmacodynamics in vivo and in vitro, CMC, pharmacokinetics, safety evaluation, and submission and registration, to realize efficient integration of R&D resources and seamless linkage of workflows.

In terms of business expansion and cooperation, the two sides will jointly build a new overseas expansion ecosystem for new drugs featuring “bringing in + going out,” characterized by bidirectional empowerment and a circular promotion mechanism, to help China’s innovative drugs better integrate into global markets. With respect to supporting overseas expansion, for Hai Lu Bio’s innovative drug pipeline, MEDIT will leverage its mature international platforms and global network to actively connect with overseas cooperation partners, and by planning and participating in top global industry conferences and other initiatives, release innovative achievements to accelerate pipeline overseas licensing and development. In promoting the “bringing in” aspect, MEDIT will, based on its international perspective and project resources, link Hai Lu Bio with high-quality overseas innovative pipelines and targets, and facilitate development and rights cooperation in the China region.

MEDIT Chairman Chen Chunlin said that he looks forward to the two sides continuing to deepen coordination in areas such as exploring more cutting-edge targets, innovative drug R&D, and globalized layout, bringing more breakthrough therapies, and jointly injecting strong momentum into the high-quality development and technological upgrading of China’s biopharmaceutical industry.

A wealth of information and precise analysis—available on the Sina Finance app